Risk factors

Celldex Therapeutics has no product revenue, relies on outside financing to fund ongoing R&D and clinical trials, and has an accumulated deficit of $1.6 billion as of December 31, 2024.

CME Group faces heavy global market competition, intense regulatory scrutiny, and technology infrastructure dependencies as a major derivatives clearinghouse.

Clinical-stage biotechnology company dependent entirely on the development of investigational COMP360 psilocybin treatment.

Compass Therapeutics is a clinical-stage biopharmaceutical company with an accumulated deficit of $365 million as of December 31, 2024. The company relies entirely on third-party contract manufacturing organizations and has never generated revenue from product sales.

Company faces ongoing operating losses with an accumulated deficit of $621.7 million as of December 31, 2024. Strategic shift toward enterprise accounts creates longer sales cycles and higher costs. International operations and expansion introduce geopolitical risks, including conflict in Ukraine. Internal control weaknesses identified in 2023 require ongoing IT general control remediation.

Cannae is exposed to management and governance conflicts through its Chairman CEO running the external Manager and overlapping boards. Portfolio companies like Restaurant Group D and B Alight and Black Knight Football carry distinct operational regulatory and market risks. Significant risks include related party agreements time allocations complex acquisitions and illiquid privately held investments.

This filing reflects an initial public risk profile dominated by structural dependencies on external managers, leveraged financing, and diverse operating subsidiaries.

Dependence on commercializing key products like Jornay, Belbuca, Xtampza, Nucynta, and Symproic drives company risks.

Columbia is heavily dependent on Asian contract manufacturers, third-party logistics providers, and discretionary consumer spending. Wholesale customers lack long-term contracts, creating high demand-forecast and order-cancellation risks. Environmental regulations target PFAS and other chemical substances used in outdoor apparel products.

Core Scientific relies entirely on CoreWeave for its HPC hosting revenue, exposing it to single-customer concentration risk. The business is heavily vulnerable to Bitcoin network hash rate increases and price volatility. Capital-intensive facility buildouts and equipment costs require continuous external financing and digital asset liquidation.

Integration costs and STB conditions from the KCS acquisition dominate the risk profile. Regulatory vulnerability in Mexico centers on the SICT concession termination risk. Carbon pricing regulations and environmental laws pose substantial cost threats.

International sales account for 43.2% of consolidated revenues, exposing operations to non-U.S. risk factors.